A novel family of peptides with potent activity against influenza A viruses

References

1. Ahmed C. M., Dabelic R., Waiboci L. W., Jager L. D., Heron L. L., Johnson H. M. 2009; SOCS-1 mimetics protect mice against lethal poxvirus infection: identification of a novel endogenous antiviral system. J Virol 83:1402–1415 [View Article][PubMed]
   [Google Scholar]
2. Altmann S. E., Jones J. C., Schultz-Cherry S., Brandt C. R. 2009; Inhibition of vaccinia virus entry by a broad spectrum antiviral peptide. Virology 388:248–259 [View Article][PubMed]
   [Google Scholar]
3. Bai F., Town T., Pradhan D., Cox J., Ashish, Ledizet M., Anderson J. F., Flavell R. A., Krueger J. K. other authors 2007; Antiviral peptides targeting the West Nile virus envelope protein. J Virol 81:2047–2055 [View Article][PubMed]
   [Google Scholar]
4. Budge P. J., Graham B. S. 2004; Inhibition of respiratory syncytial virus by RhoA-derived peptides: implications for the development of improved antiviral agents targeting heparin-binding viruses. J Antimicrob Chemother 54:299–302 [View Article][PubMed]
   [Google Scholar]
5. Cheng G., Montero A., Gastaminza P., Whitten-Bauer C., Wieland S. F., Isogawa M., Fredericksen B., Selvarajah S., Gallay P. A. other authors 2008; A virocidal amphipathic α-helical peptide that inhibits hepatitis C virus infection in vitro . Proc Natl Acad Sci U S A 105:3088–3093 [View Article][PubMed]
   [Google Scholar]
6. Cooper D. A., Lange J. M. 2004; Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development. Lancet Infect Dis 4:426–436 [View Article][PubMed]
   [Google Scholar]
7. Howard W., Hayman A., Lackenby A., Whiteley A., Londt B., Banks J., McCauley J., Barclay W. 2007; Development of a reverse genetics system enabling the rescue of recombinant avian influenza virus A/Turkey/England/50-92/91 (H5N1). Avian Dis 51:Suppl.393–395 [View Article][PubMed]
   [Google Scholar]
8. Jing X., Ma C., Ohigashi Y., Oliveira F. A., Jardetzky T. S., Pinto L. H., Lamb R. A. 2008; Functional studies indicate amantadine binds to the pore of the influenza A virus M2 proton-selective ion channel. Proc Natl Acad Sci U S A 105:10967–10972 [View Article][PubMed]
   [Google Scholar]
9. Jones J. C., Turpin E. A., Bultmann H., Brandt C. R., Schultz-Cherry S. 2006; Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells. J Virol 80:11960–11967 [View Article][PubMed]
   [Google Scholar]
10. Matthews T., Salgo M., Greenberg M., Chung J., DeMasi R., Bolognesi D. 2004; Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov 3:215–225 [View Article][PubMed]
    [Google Scholar]
11. Mujtaba M. G., Flowers L. O., Patel C. B., Patel R. A., Haider M. I., Johnson H. M. 2005; Treatment of mice with the suppressor of cytokine signaling-1 mimetic peptide, tyrosine kinase inhibitor peptide, prevents development of the acute form of experimental allergic encephalomyelitis and induces stable remission in the chronic relapsing/remitting form. J Immunol 175:5077–5086[PubMed] [CrossRef]
    [Google Scholar]
12. Sleeman K., Mishin V. P., Deyde V. M., Furuta Y., Klimov A. I., Gubareva L. V. 2010; In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses. Antimicrob Agents Chemother 54:2517–2524 [View Article][PubMed]
    [Google Scholar]
13. Thompson W. W., Shay D. K., Weintraub E., Brammer L., Bridges C. B., Cox N. J., Fukuda K. 2004; Influenza-associated hospitalizations in the United States. JAMA 292:1333–1340 [View Article][PubMed]
    [Google Scholar]
14. Triana-Baltzer G. B., Gubareva L. V., Nicholls J. M., Pearce M. B., Mishin V. P., Belser J. A., Chen L. M., Chan R. W., Chan M. C. other authors 2009; Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein. PLoS ONE 4:e7788 [View Article][PubMed]
    [Google Scholar]